New 2026 Cholesterol Guidelines: What Actually Changed

If your last physical involved a slightly different conversation about cholesterol than the one before it, you weren't imagining it. In March 2026, the American College of Cardiology and American Heart Association released a new joint guideline on managing dyslipidemia, the first full update since 2018. It changes what "good" looks like on a lipid panel, adds a test most people have never heard of, and quietly moved millions of people into a category where a statin conversation is now on the table. Here is what actually changed and what it means for you, without the hype.

Cholesterol guidelines have a history of swinging back and forth. The 2013 update moved doctors away from chasing a specific LDL number and toward broad risk categories, and the 2018 revision mostly kept that approach while adding more nuance for edge cases. If you've felt like the goalposts move every few years, that's a fair read. The difference this time is that the new guideline is built on a decade of additional trial data, including newer LDL-lowering drug classes, and on growing evidence that lifetime exposure to high LDL matters as much as any single reading.

The headline change: specific LDL targets are back

The 2013 and 2018 guidelines moved away from hard LDL numbers and toward broader risk categories. The 2026 guideline reverses that. It reintroduces specific LDL cholesterol targets based on a person's cardiovascular risk:

• Under 55 mg/dL: the goal for people already at very high risk, such as those who have had a heart attack or stroke
• Under 70 mg/dL: the goal for people at high risk based on their calculated cardiovascular risk
• Under 100 mg/dL: the goal for people at lower baseline risk

The guideline also widened who gets a formal risk assessment in the first place, extending it from the old 40-75 age range down to 30 and up to 79, and it now asks clinicians to estimate risk over both 10 years and 30 years instead of just the next decade. That longer view matters most for younger adults, whose 10-year risk can look reassuringly low even when decades of exposure to high LDL is quietly doing damage.

A new test: Lp(a), checked once

The other major addition is lipoprotein(a), or Lp(a), a cholesterol particle that is almost entirely determined by genetics rather than diet or lifestyle. The new guideline recommends every adult get it checked once in their lifetime. Unlike LDL, it does not need repeat testing, because it stays roughly stable from early adulthood on.

Why it matters: elevated Lp(a) raises cardiovascular risk independent of LDL, by an estimated 40 percent at levels around 125 nmol/L and roughly double at 250 nmol/L. Because it is inherited in a dominant pattern, a high result is also a signal to consider testing for close relatives, since they may share the same risk without knowing it.

Lp(a) has been on researchers' radar for years, but it hasn't been part of routine care because, until recently, there wasn't much a doctor could offer someone with a high result beyond managing everything else more aggressively. That's part of why the guideline frames it as informational rather than a call to action on its own: a high Lp(a) doesn't change your diet or exercise plan, but it can shift how seriously your doctor takes your other numbers and how early you two start talking about them.

Why "statin eligible" numbers jumped

A JAMA analysis published in July 2026 estimated that the new guideline makes about 87.5 million American adults ages 30 to 79 eligible for statin therapy for primary prevention, more than half of the non-cardiovascular-disease population in that age range. Of those, roughly 21.5 million are newly eligible compared with the old 2018 guideline, and they tend to be younger with lower calculated risk than people who already qualified. Among adults in their 70s specifically, the analysis found 93 percent now meet the criteria to discuss a statin.

To be clear about what "eligible" means here: it describes who a doctor should now discuss statin therapy with based on calculated risk, not a blanket recommendation that everyone in that group start taking one. That decision still depends on your full risk picture, your preferences, and a conversation with your own doctor. This post isn't the place to weigh in on whether any individual should take a statin, only to explain why the criteria shifted.

The gap: most people don't know where they stand

A companion study from Mass General Brigham researchers, published in JAMA, analyzed national health survey data representative of about 178 million U.S. adults and compared their LDL levels against the new goals. The findings are sobering. Nearly one in three adults without existing heart disease have LDL above their new target, and among people who have already had a heart attack, stroke, or other cardiovascular event, that figure jumps to almost four in five. Perhaps the most striking number: among adults without heart disease who were above their target, about three in four were not on any cholesterol-lowering medication at all.

That gap is really the story underneath the story. New targets only help if people know their own numbers well enough to notice when they miss them.

What this means for you

None of this requires panic, and none of it means you should change anything about a medication on your own. If you got a high LDL result recently and your doctor gave you a few months to try diet and exercise changes before revisiting medication, the new targets are worth knowing before that retest, not after. A number that would have passed under the old, looser categories might now sit above your specific goal depending on your calculated risk. That's not a reason to worry between now and your appointment, just a reason to confirm which of the three target bands actually applies to you. From there, this is a reasonable moment to close a few more gaps:

• Ask if you've had an Lp(a) test. Most people haven't, and it's a one-time blood draw, not a recurring commitment.
• Get your actual LDL number, not just a "normal" or "high" label. The new tiered targets mean the same number can be fine for one person and a signal for another, depending on overall risk.
• Bring your numbers, not just your memory, to your next appointment. A trend across a few tests tells your doctor far more than a single snapshot does.
• If diet and lifestyle are part of your plan, soluble fiber and saturated fat intake are two of the levers with the most consistent evidence behind them. Our guide to soluble fiber and psyllium and our 90-day natural lowering plan walk through both in more detail.

Closing

Guidelines like this one are really just an update to the target, not a verdict on any one person. Whether your own number moved from "fine" to "worth watching" depends entirely on your individual risk, and that's a conversation for your doctor, not a headline. The useful move is the same as it always was: know your actual numbers, track how they move over time, and bring that information into the room instead of guessing.

That's the gap this whole story keeps pointing back to. Millions of people above their new goal simply don't know it yet, and knowing is the cheapest part of the whole equation. Cholesterol Drop logs your LDL, HDL, triglycerides, and Lp(a) alongside the saturated fat and fiber that influence them, so when your next panel comes back, you'll already know whether the changes you made are working, not just what the label says.